Improved Binding Activity of Antibodies against Major Histocompatibility Complex Class I Chain-Related Gene A by Phage Display Technology for Cancer-Targeted Therapy

Table 1

Primers for PCR-random mutation of HCDR3 region of anti-MICA antibodies.

	Forward primers	Reverse primers	Size of product; (bp)
(1) anti-MICA: WW2G8	5′-TAT TgT NNY NNY NNY NNY NNY; NNY NNY NNY NNY NNY NNY NNY; Tgg ggT-3′	5′-ACC CCA RNN RNN RNN RNN RNN; RNN RNN RNN RNN RNN RNN RNN; ACA ATA-3′	5000 bp
(2) anti-MICA: WW6B7	5′-TAC TgT NNY NNY NNY NNY NNY; NNY NNY NNY NNY NNY NNY NNY; NNY  NNY Tgg ggC-3′	5′- gCC CCA RNN RNN RNN RNN RNN; RNN RNN RNN RNN RNN RNN RNN; RNN RNN ACA gTA-3′	5000 bp
(3) anti-MICA: WW9B8	5′-TAT TgT NNY NNY NNY NNY NNY; NNY NNY NNY NNY NNY NNY NNY; Tgg ggT-3′	5′-ACC CCA RNN RNN RNN RNN RNN; RNN RNN RNN RNN RNN RNN RNN; ACA ATA-3′	5000 bp